ATHE
Price
$3.48
Change
-$0.00 (-0.00%)
Updated
Apr 28 closing price
Capitalization
45.53M
ICCC
Price
$5.50
Change
-$0.00 (-0.00%)
Updated
Apr 28 closing price
Capitalization
49.47M
15 days until earnings call
Ad is loading...

ATHE vs ICCC

Header iconATHE vs ICCC Comparison
Open Charts ATHE vs ICCCBanner chart's image
Alterity Therapeutics
Price$3.48
Change-$0.00 (-0.00%)
Volume$10.85K
Capitalization45.53M
ImmuCell
Price$5.50
Change-$0.00 (-0.00%)
Volume$14.36K
Capitalization49.47M
ATHE vs ICCC Comparison Chart
Loading...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHE vs. ICCC commentary
Apr 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHE is a StrongBuy and ICCC is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 29, 2025
Stock price -- (ATHE: $3.48 vs. ICCC: $5.50)
Brand notoriety: ATHE and ICCC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHE: 50% vs. ICCC: 62%
Market capitalization -- ATHE: $45.53M vs. ICCC: $49.47M
ATHE [@Biotechnology] is valued at $45.53M. ICCC’s [@Biotechnology] market capitalization is $49.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $272.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHE’s FA Score shows that 0 FA rating(s) are green whileICCC’s FA Score has 0 green FA rating(s).

  • ATHE’s FA Score: 0 green, 5 red.
  • ICCC’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATHE and ICCC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ICCC’s TA Score shows that 6 TA indicator(s) are bullish.

  • ICCC’s TA Score: 6 bullish, 3 bearish.

Price Growth

ATHE (@Biotechnology) experienced а +0.77% price change this week, while ICCC (@Biotechnology) price change was +2.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.96%. For the same industry, the average monthly price growth was -1.16%, and the average quarterly price growth was -9.88%.

Reported Earning Dates

ATHE is expected to report earnings on Feb 28, 2025.

ICCC is expected to report earnings on May 14, 2025.

Industries' Descriptions

@Biotechnology (+7.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ICCC($49.5M) has a higher market cap than ATHE($45.5M). ICCC YTD gains are higher at: 6.796 vs. ATHE (5.136). ICCC has higher annual earnings (EBITDA): -551.81K vs. ATHE (-19.88M). ATHE has more cash in the bank: 4.54M vs. ICCC (3.81M). ATHE has less debt than ICCC: ATHE (106K) vs ICCC (15.5M). ICCC has higher revenues than ATHE: ICCC (23.8M) vs ATHE (0).
ATHEICCCATHE / ICCC
Capitalization45.5M49.5M92%
EBITDA-19.88M-551.81K3,602%
Gain YTD5.1366.79676%
P/E RatioN/AN/A-
Revenue023.8M-
Total Cash4.54M3.81M119%
Total Debt106K15.5M1%
FUNDAMENTALS RATINGS
ATHE vs ICCC: Fundamental Ratings
ATHE
ICCC
OUTLOOK RATING
1..100
234
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
10084
SMR RATING
1..100
9892
PRICE GROWTH RATING
1..100
3539
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ICCC's Valuation (88) in the Medical Specialties industry is in the same range as ATHE (89) in the Biotechnology industry. This means that ICCC’s stock grew similarly to ATHE’s over the last 12 months.

ICCC's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as ATHE (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to ATHE’s over the last 12 months.

ICCC's SMR Rating (92) in the Medical Specialties industry is in the same range as ATHE (98) in the Biotechnology industry. This means that ICCC’s stock grew similarly to ATHE’s over the last 12 months.

ATHE's Price Growth Rating (35) in the Biotechnology industry is in the same range as ICCC (39) in the Medical Specialties industry. This means that ATHE’s stock grew similarly to ICCC’s over the last 12 months.

ICCC's P/E Growth Rating (99) in the Medical Specialties industry is in the same range as ATHE (100) in the Biotechnology industry. This means that ICCC’s stock grew similarly to ATHE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ICCC
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 7 days ago
77%
Declines
ODDS (%)
Bearish Trend 26 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
View a ticker or compare two or three
Ad is loading...
ICCC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NWBI11.850.10
+0.85%
Northwest Bancshares
EQIX844.686.58
+0.79%
Equinix
SMBK30.120.03
+0.10%
SmartFinancial
TOON0.56N/A
-0.12%
Kartoon Studios
GLBE35.76-0.46
-1.27%
Global-E Online Ltd

ICCC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICCC
1D Price
Change %
ICCC100%
N/A
NKTX - ICCC
43%
Loosely correlated
-4.74%
ATHE - ICCC
27%
Poorly correlated
-0.02%
BOLT - ICCC
26%
Poorly correlated
-5.08%
IMMP - ICCC
23%
Poorly correlated
+1.23%
MYNDF - ICCC
23%
Poorly correlated
N/A
More